A number of PD-L1 IHC tests were independently codeveloped to support specific anti-PD-(L)1 programs, and the lack of standardization between these IHC requires harmonization of these assays in the clinic, as well as consensus on the scoring algorithms and cut-off levels to define positive PD-L1 status across various tumor types. Here, CD274 is linked to neoplasm.